M Battegay
How reliable is an undetectable viral load?
Combescure C, Hirschel B, Vernazza P, Bernasconi E, Battegay M, Rauch A, Furrer H, Cavassini M, Ledergerber B, Vallier N, Swiss HIV Cohort Study. How reliable is an undetectable viral load?. HIV medicine 2009; 10:470-6.
Sep 1, 2009How reliable is an undetectable viral load?
Sep 1, 2009HIV medicine 2009; 10:470-6
Combescure Christophe, Hirschel B, Vernazza Pietro, Bernasconi E, Battegay M, Rauch A, Furrer H, Cavassini M, Ledergerber B, Vallier N, Swiss HIV Cohort Study
Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study
Wolbers M, Battegay M, Hirschel B, Bernasconi E, Schmid P, Weber R, Cavassini M, Rickenbach M, Furrer H, Bucher H, Swiss HIV Cohort Study. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV medicine 2008; 9:397-405.
Jul 1, 2008Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study
Jul 1, 2008HIV medicine 2008; 9:397-405
Wolbers M, Battegay M, Hirschel B, Bernasconi E, Schmid Patrick, Weber R, Cavassini M, Rickenbach M, Furrer H, Bucher H C, Swiss HIV Cohort Study
Detection of drug-resistant HIV minorities in clinical specimens and therapy failure
Louvel S, Battegay M, Vernazza P, Bregenzer T, Klimkait T, Hamy F, Swiss HIV Cohort Study. Detection of drug-resistant HIV minorities in clinical specimens and therapy failure. HIV medicine 2008; 9:133-41.
Mar 1, 2008Detection of drug-resistant HIV minorities in clinical specimens and therapy failure
Mar 1, 2008HIV medicine 2008; 9:133-41
Louvel S, Battegay M, Vernazza Pietro, Bregenzer T, Klimkait T, Hamy F, Swiss HIV Cohort Study
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006
Nguyen A, Hirschel B, Perneger T, Schmid P, Tarr P, Evison J, Opravil M, Battegay M, Bernasconi E, Schiffer V, Calmy A, Swiss HIV Cohort Study. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV medicine 2008; 9:142-50.
Mar 1, 2008Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006
Mar 1, 2008HIV medicine 2008; 9:142-50
Nguyen A, Hirschel B, Perneger T, Schmid Patrick, Tarr P E, Evison J-M, Opravil M, Battegay M, Bernasconi E, Schiffer V, Calmy A, Swiss HIV Cohort Study
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV medicine 2006; 7:404-10.
Sep 1, 2006Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Sep 1, 2006HIV medicine 2006; 7:404-10
Glass T R, Bucher H C, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza Pietro, Weber R, Wolbers M, Ungsedhapand C, Swiss HIV Cohort Study
Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Fehr J, Battegay M, Spirig R, Jäger H, Vernazza P, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Swiss HIV Cohort Study. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33:249-56.
Aug 1, 2005Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Aug 1, 2005Infection 2005; 33:249-56
Fehr J S, Battegay M, Spirig R, Jäger H, Vernazza Pietro, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Swiss HIV Cohort Study
[Status febrilis and unconsciousness]
Sawatzki M, Hatz C, Buser A, Battegay M. [Status febrilis and unconsciousness]. Der Internist 2005; 46:202-5.
Feb 1, 2005[Status febrilis and unconsciousness]
Feb 1, 2005Der Internist 2005; 46:202-5
Sawatzki Mikael, Hatz C, Buser A, Battegay M
Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection
Wagels T, Amiet R, Battegay M, Guex A, Opravil M, Vernazza P, Swiss HIV Cohort Study Group. Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2004; 134:678-80.
Nov 13, 2004Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection
Nov 13, 2004Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2004; 134:678-80
Wagels T, Amiet R, Battegay M, Guex A C, Opravil M, Vernazza Pietro, Swiss HIV Cohort Study Group
[Smoking cessation for HIV infected patients]
Voggensperger J, Nicca D, Battegay M, Zellweger J, Spirig R. [Smoking cessation for HIV infected patients]. Pflege 2003; 16:283-8.
Oct 1, 2003[Smoking cessation for HIV infected patients]
Oct 1, 2003Pflege 2003; 16:283-8
Voggensperger Jacqueline, Nicca Dunja, Battegay M, Zellweger J P, Spirig Rebecca
Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
Bucher H, Battegay M, Minder C, Vernazza P, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine 2002; 3:247-53.
Oct 1, 2002Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
Oct 1, 2002HIV medicine 2002; 3:247-53
Bucher H C, Battegay M, Minder C, Vernazza Pietro, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study
[Hospitalizations in a cohort of 175 severely drug-addicted patients of a medically managed opiate withdrawal project]
Hoffmann M, Haller P, Bucher H, Gyr N, Battegay M. [Hospitalizations in a cohort of 175 severely drug-addicted patients of a medically managed opiate withdrawal project]. Praxis 2001; 90:2094-101.
Nov 29, 2001[Hospitalizations in a cohort of 175 severely drug-addicted patients of a medically managed opiate withdrawal project]
Nov 29, 2001Praxis 2001; 90:2094-101
Hoffmann Matthias, Haller P, Bucher H C, Gyr N, Battegay M
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
Yerly S, Perrin L, Hirschel B, Rickenbach M, Bru J, Veuthey A, Battegay M, Telenti A, Flepp M, Vernazza P, Chave J, Rizzardi P, Vora S, Swiss HIV Cohort Study. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (London, England) 2001; 15:2287-92.
Nov 23, 2001Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
Nov 23, 2001AIDS (London, England) 2001; 15:2287-92
Yerly S, Perrin L, Hirschel B, Rickenbach M, Bru J P, Veuthey A L, Battegay M, Telenti A, Flepp M, Vernazza Pietro, Chave J P, Rizzardi P, Vora S, Swiss HIV Cohort Study
Importance of mental health assessment in HIV-infected outpatients
Zinkernagel C, Battegay M, Vernazza P, Werder V, Kiss A, Rauchfleisch U, Volkart A, Ledergerber B, Amiet R, Rickenbach M, Taffé P, Swiss HIV Cohort Study. Importance of mental health assessment in HIV-infected outpatients. Journal of acquired immune deficiency syndromes (1999) 2001; 28:240-9.
Nov 1, 2001Importance of mental health assessment in HIV-infected outpatients
Nov 1, 2001Journal of acquired immune deficiency syndromes (1999) 2001; 28:240-9
Zinkernagel C, Battegay M, Vernazza Pietro, Werder V, Kiss A, Rauchfleisch U, Volkart A C, Ledergerber B, Amiet R, Rickenbach M, Taffé P, Swiss HIV Cohort Study
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay J, Telenti A, Flepp M, Greub G, Francioli P, Vernazza P, Hirschel B, Battegay M, Furrer H, Bernasconi E, Ledergerber B, Boubaker K, Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-7.
Oct 20, 2001Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Oct 20, 2001Lancet 2001; 358:1322-7
Fellay J, Telenti A, Flepp M, Greub G, Francioli P, Vernazza Pietro, Hirschel B, Battegay M, Furrer H, Bernasconi E, Ledergerber B, Boubaker K, Swiss HIV Cohort Study
A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia
Miserez A, Muller P, Barella L, Schwietert M, Erb P, Vernazza P, Battegay M, Swiss HIV Cohort Study. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS (London, England) 2001; 15:2045-9.
Oct 19, 2001A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia
Oct 19, 2001AIDS (London, England) 2001; 15:2045-9
Miserez A R, Muller P Y, Barella L, Schwietert M, Erb P, Vernazza Pietro, Battegay M, Swiss HIV Cohort Study
Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection
Bisset L, Opravil M, Grob P, Weber R, Dubs R, Vernazza P, Battegay M, Fischer M, Cone R, Swiss HIV Cohort Study. Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection. Journal of acquired immune deficiency syndromes (1999) 2001; 27:266-71.
Jul 1, 2001Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection
Jul 1, 2001Journal of acquired immune deficiency syndromes (1999) 2001; 27:266-71
Bisset L R, Opravil M, Grob P J, Weber R, Dubs R W, Vernazza Pietro, Battegay M, Fischer M, Cone R W, Swiss HIV Cohort Study
Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
Battegay M, Hirschel B, Bedoucha V, Morgenthaler S, Jaccard C, Malinverni R, Erb P, Sendi P, Flepp M, Bernasconi E, Vernazza P, Swiss HIV Cohort Study. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. HIV medicine 2001; 2:35-42.
Jan 1, 2001Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
Jan 1, 2001HIV medicine 2001; 2:35-42
Battegay M, Hirschel B, Bedoucha V, Morgenthaler S, Jaccard C, Malinverni R, Erb P, Sendi P, Flepp M, Bernasconi E, Vernazza Pietro, Swiss HIV Cohort Study
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J, Boggian K, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
Nov 25, 2000Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
Nov 25, 2000Lancet 2000; 356:1800-5
Greub G, Flepp M, Francioli P, Janin P, Hirschel B, Piffaretti J C, Boggian Katia, Erb P, Bürgisser P, Furrer H, Perrin L, Grob P, Battegay M, Ledergerber B, Telenti A
Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients
Berneis K, Battegay M, Bassetti S, Nuesch R, Leisibach A, Bilz S, Keller U. Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients. European journal of clinical investigation 2000; 30:87-94.
Jan 1, 2000Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients
Jan 1, 2000European journal of clinical investigation 2000; 30:87-94
Berneis K, Battegay M, Bassetti S, Nuesch R, Leisibach A, Bilz Stefan, Keller U
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA : the journal of the American Medical Association 1999; 282:2220-6.
Dec 15, 1999AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Dec 15, 1999JAMA : the journal of the American Medical Association 1999; 282:2220-6
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza Pietro, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A